Reshoring Generic Drug Production: The Obstacles America Faces
Trump's push to revive domestic generic drug manufacturing runs into steep structural barriers, as India's dominance in the sector illustrates.
President Trump has made reviving American pharmaceutical manufacturing a central policy goal, but the generic drug sector presents some of the most formidable challenges to that ambition. India's entrenched position as a global supplier of low-cost generics offers a clear illustration of how difficult that reversal would be to engineer.
Cheap labor is among the most fundamental advantages that countries like India hold over the United States. Generic drug production is largely a commodity business defined by razor-thin margins, and labor costs embedded throughout manufacturing and packaging operations make domestic production significantly more expensive before other factors are even considered.
Read more Fed Approves Fleur Capital Corporation Bank Application →
Global supply chains compound the problem further. Active pharmaceutical ingredients — the chemical compounds that give drugs their medical effect — are sourced predominantly from India and China, meaning that even drugs labeled as American-made often depend on overseas inputs at critical stages of production. Rebuilding those upstream supply relationships domestically would require years of investment and regulatory groundwork.
The structural gap between what American-made generics would cost to produce and what consumers, insurers, and government programs currently pay raises serious questions about market viability. Without sustained subsidies, mandates, or protective tariffs, economic incentives may be insufficient to attract the scale of private investment needed to shift the industry's center of gravity back to the United States.
Continue reading at NYT > Business
